tiprankstipranks
Advertisement
Advertisement

ATYR Stock Latest News

aTyr Pharma Granted Nasdaq Extension to Regain Compliance
Company AnnouncementsaTyr Pharma Granted Nasdaq Extension to Regain Compliance
12d ago
8K
ATYR
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis
PremiumCompany Announcements
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis
17d ago
ATYR
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data
PremiumCompany Announcements
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data
19d ago
8K
ATYR
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
PremiumThe Fly
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
1M ago
ATYR
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
PremiumThe Fly
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
1M ago
ATYR
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
PremiumThe FlyMidday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
1M ago
BX
DLO
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
Premium
The Fly
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
1M ago
ATYR
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
Premium
Ratings
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
1M ago
ATYR
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
PremiumRatings
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
1M ago
ATYR
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
PremiumThe Fly
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
1M ago
ATYR
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
PremiumCompany Announcements
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
1M ago
8K
ATYR
ATYR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ATYR Upcoming Earnings Report: What to Expect?
1M ago
ATYR
aTyr Pharma Inc options imply 14.1% move in share price post-earnings
PremiumThe FlyaTyr Pharma Inc options imply 14.1% move in share price post-earnings
1M ago
ATYR
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
Premium
Company Announcements
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
4M ago
ATYR
aTyr Pharma reports Q4 EPS (14c), consensus (17c)
Premium
The Fly
aTyr Pharma reports Q4 EPS (14c), consensus (17c)
4M ago
ATYR
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
PremiumThe Fly
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
5M ago
ATYR
aTyr Pharma Receives Nasdaq Deficiency Notice
PremiumCompany Announcements
aTyr Pharma Receives Nasdaq Deficiency Notice
7M ago
8K
ATYR
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
PremiumMarket News
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
7M ago
ATYR
aTyr Pharma Reports Increased Losses Amid Rising R&D Costs
PremiumCompany Announcements
aTyr Pharma Reports Increased Losses Amid Rising R&D Costs
7M ago
ATYR
aTyr Pharma reports Q3 EPS (26c), consensus (18c)
PremiumThe FlyaTyr Pharma reports Q3 EPS (26c), consensus (18c)
8M ago
ATYR
aTyr Pharma Inc options imply 21.3% move in share price post-earnings
Premium
The Fly
aTyr Pharma Inc options imply 21.3% move in share price post-earnings
8M ago
ATYR
ATYR Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ATYR Earnings this Week: How Will it Perform?
8M ago
ATYR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >